COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Chang, C. W. [1 ]
Lang, H. C. [1 ]
机构：
[1] Natl Yang Ming Univ, Taipei, TPE, Taiwan
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.696
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG17
引用
收藏
页码：S165 / S166
页数：3
相关论文
共 50 条
  • [21] Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer
    Georgieva, M.
    Aguiar, P., Jr.
    Lima, J. P.
    Haaland, B.
    Lopes, G.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2148 - S2149
  • [22] Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer
    Georgieva, Mina
    da Silveira Nogueira Lima, Joao P.
    Aguiar, Pedro
    Lopes, Gilberto de Lima, Jr.
    Haaland, Benjamin
    [J]. LUNG CANCER, 2018, 124 : 248 - 254
  • [23] Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer
    Franchi, Matteo
    Pellegrini, Giacomo
    Corrao, Giovanni
    [J]. PHARMACEUTICALS, 2022, 15 (04)
  • [24] Treatment patterns and cost-effectiveness of first line treatment of advanced non-squamous non-small cell lung cancer in Medicare patients
    Gilden, Daniel M.
    Kubisiak, Joanna M.
    Pohl, Gerhardt M.
    Ball, Daniel E.
    Gilden, David E.
    John, William J.
    Wetmore, Stewart
    Winfree, Katherine B.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) : 151 - 161
  • [25] The cost of non-small cell lung cancer (NSCLC) treatment
    Vergnenegre, A.
    [J]. ONCOLOGIE, 2012, 14 (05) : 310 - 315
  • [26] Second-line treatment of advanced non-small cell lung cancer
    Gridelli, Cesare
    Ardizzoni, Andrea
    Ciardiello, Fortunato
    Hanna, Nasser
    Heymach, John V.
    Perrone, Francesco
    Rosell, Rafael
    Shepherd, Frances A.
    Thatcher, Nick
    Vansteenkiste, Johan
    De Petris, Luigi
    Di Maio, Massimo
    De Marinis, Filippo
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (04) : 430 - 440
  • [27] WORDS (EXCLUDING TATLE AND AUTHORS: 300) TITLE: COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE TREATMENT OF SECOND-LINE ADVANCED SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SPAIN
    Gonzalez Garcia, P.
    Felip, E.
    Garrido, P.
    Trigo, J.
    Ortega-Joaquin, N.
    Echave, M.
    Jimenez, S.
    Oyaguez, I
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A732 - A733
  • [28] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Nan Qiao
    Ralph Insinga
    Gilberto de Lima Lopes Junior
    John Cook
    Martin Sénécal
    [J]. PharmacoEconomics - Open, 2021, 5 : 365 - 383
  • [29] A Review of Cost-Effectiveness Studies of Pembrolizumab Regimens for the Treatment of Advanced Non-small Cell Lung Cancer
    Qiao, Nan
    Insinga, Ralph
    Lopes Junior, Gilberto de Lima
    Cook, John
    Senecal, Martin
    [J]. PHARMACOECONOMICS-OPEN, 2021, 5 (03) : 365 - 383
  • [30] COST-EFFECTIVENESS OF GEFITINIB VERSUS DOUBLET CHEMOTHERAPY IN FIRST-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN SWEDEN
    Jacob, J.
    Henriksson, M.
    Brattstrom, D.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A270 - A270
12345